Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Lost Money on Arvinas, Inc. (ARVN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and Chairperson Noah Berkowitz - Chief Medical Officer Andrew Sake - Chief Financial Officer Angela Cacace - Chief Scientific Officer Conference Call Participants Akash Tewari - Jefferies Brad Canino - Stifel Etzer Darout - BMO Capital Markets Ellie Merle - UBS Derek Archila - Wells Fargo Li Watsek - Cantor Ted Tenthoff - Bipolar Sandler Tazeen Ahmad - Bank of America Michael Schmidt - Guggenheim Tyler Van Buren - TD Cowen Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup Matthew Biegler - Oppenheimer Operator Thank you for standing by. At this time, I'd like to welcome everyone to Arvinas Third Quarter 2024 Earnings Call.
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 per share a year ago.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.25 per share a year ago.
